Shenzhen Neptunus Bioengineering Co., Ltd.

Shenzhen Stock Exchange 000078.SZ

Shenzhen Neptunus Bioengineering Co., Ltd. Operating Income for the year ending December 31, 2023: USD -206.77 M

Shenzhen Neptunus Bioengineering Co., Ltd. Operating Income is USD -206.77 M for the year ending December 31, 2023, a -249.83% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Shenzhen Neptunus Bioengineering Co., Ltd. Operating Income for the year ending December 31, 2022 was USD 138.01 M, a -49.28% change year over year.
Shenzhen Neptunus Bioengineering Co., Ltd. Operating Income for the year ending December 31, 2021 was USD 272.08 M, a -7.32% change year over year.
Shenzhen Neptunus Bioengineering Co., Ltd. Operating Income for the year ending December 31, 2020 was USD 293.56 M, a -19.95% change year over year.
Shenzhen Neptunus Bioengineering Co., Ltd. Operating Income for the year ending December 31, 2019 was USD 366.72 M, a 145.37% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Shenzhen Stock Exchange: 000078.SZ

Shenzhen Neptunus Bioengineering Co., Ltd.

CEO	Mr. Feng Zhang
IPO Date	Dec. 18, 1998
Location	China
Headquarters	Wang Yinhe Technology Building
Employees	9,093
Sector	Healthcare
Industries Pharmaceuticals Biotechnology

Description

Shenzhen Neptunus Bioengineering Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products primarily in China. It offers drugs in the fields of anti-tumor, cardio-cerebrovascular, marine drugs, and other fields. The company was founded in 1989 and is based in Shenzhen, China.

Key trends

Past 5 years